Cigarette smoking is the first risk factor for lung cancer and one of the leading causes of...
Luca Di Tommaso
Education and Academic Background
- 1997 M.D., “summa cum laude”, University of Bologna, School of Medicine, Bologna (Italy)
- 2003 Postgraduate Medical School in Pathology, University of Bologna, Bologna (Italy)
- 2014 Fellowship, International Academy of Cytology
- 2004 to 2012: Adjunct Professor of Pathology, University of Milan, School of Medicine, Milan
- 2012 to 09/2015 Assistant Professor of Pathology, University of Milan, School of Medicine, Milan
- 10/2015 to date: Assistant professor of Pathology, Humanitas University, Rozzano, Milan
- 2003 to present: Staff Pathologist, Humanitas Clinical Institute, Rozzano, Milan
- 2012 to present: Head of Section of Liver Pathology, Pathology Unit, Humanitas Clinical Institute.
- 2012 to present: Head of Section of Cytology, Pathology Unit, Humanitas Clinical Institute.
Scientific and Research Interests
The main field of my research is liver pathology, with particular regard to the identification of tissue biomarkers (diagnostic, prognostic and predictive) and to the study of morphological and phenotypical aspects of early phases of human hepatocarcinogenesis. I have been involved in the diagnostic guidelines of hepatocellular tumors, by national and international society. In addition I am also interested in the study of breast, thymic and thyroid pathology as well as in History of Medicine.
The author of 76 peer review publications on international journals, and is the first author in 28 of them. (IF: 221; H index: 16), and more than 100 short communications to international congress, 30 with personal invitation.
- Di Tommaso L et al. Diagnostic value of HSP70, glypican 3 and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007; 45(3): 725-735
- Di Tommaso L, et al. The application of a panel of markers (hsp 70, gpc3, gs) in liver biopsies is useful for HCC detection. Journal of Hepatology 2009; 50(4): 746-54
- Di Tommaso L, et al. Diagnostic accuracy of chlatryn heavy chain staining in a markers panel for the diagnosis of small HCC. Hepatology, 2011; 53(5): 1549-1557
- Di Tommaso L, et al. Advanced precancerous lesions of the liver. Best Practice Res Clin Gastroenterol 2013; 27(2): 269-284
- Nault JC, et al. TERT promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology, 2014; 60(6):1983-92
- Perra A, et al . YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol. 2014; 61(5):1088-96.
- Sciarra A, et al. TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma. Liver Int 2015;35(11):2466-73
- Sciarra A, et al. Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications. J Hepatol. 2016;64(1):87-93
- Nguyen T, et al. Combined use of heat shock protein 70 and glutamine synthetase is useful in the distinction of typical hepatocellular adenoma from atypical hepatocellular neoplasms and well-differentiated hepatocellular carcinoma. Modern Pathology, 2016 29(3):283-92
- Rizzo F, et al. Specific patterns of PIWI-interacting small noncoding RNA expression in dysplastic liver nodules and hepatocellular carcinoma. Oncotarget, in print